Literature DB >> 34632570

Tildrakizumab: short-term efficacy and safety in real clinical practice.

Manuel Galán-Gutierrez1, Lourdes Rodriguez-Fernandez Freire2, Ricardo Ruiz-Villaverde3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34632570     DOI： 10.1111/ijd.15840

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   3.204


× No keyword cloud information.
  4 in total

1.  Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.

Authors:  Marco Galluzzo; Marina Talamonti; Arnaldo Cioni; Virginia Maffei; Ruslana Gaeta Shumak; Lorenzo Tofani; Luca Bianchi; Elena Campione
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

2.  Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.

Authors:  Giacomo Caldarola; Marco Galluzzo; Nicoletta Bernardini; Laura Calabrese; Marta Grimaldi; Gaia Moretta; Gianluca Pagnanelli; Ruslana Gaeta Shumak; Marina Talamonti; Lorenzo Tofani; Sabatino Pallotta; Ketty Peris; Concetta Potenza; Clara De Simone; Elena Campione
Journal:  Dermatol Ther       Date:  2022-04-11       Impact factor: 3.858

3.  Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain).

Authors:  Ricardo Ruiz-Villaverde; Lourdes Rodriguez Fernandez-Freire; Pilar Font-Ugalde; Manuel Galan-Gutierrez
Journal:  J Clin Med       Date:  2022-08-30       Impact factor: 4.964

4.  Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.

Authors:  Diamant Thaçi; Sascha Gerdes; Kristian Gaarn Du Jardin; Jean-Luc Perrot; Lluís Puig
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.